Results 11 to 20 of about 5,525 (123)

Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer Impactos do polimorfismo genético do citocromo P450 2D6 (CYP2D6) na terapia com tamoxifeno para câncer de mama [PDF]

Revista Brasileira de Ginecologia e Obstetrícia, 2018
Tamoxifen (TMX) is the main drug used both in pre and postmenopausal women as adjuvant treatment for hormone receptor-positive breast cancer. An important barrier to the use of TMXis the development ofdrug resistance causedby molecular processes related ...
Lucas Soares Bezerra, Marcelo Antônio Oliveira Santos-Veloso, Natanael da Silva Bezerra Junior, Lucilia Carvalho da Fonseca, Wivianne Lisley Andrade Sales   +4 more
doaj   +1 more source

Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity [PDF]

American Journal of Epidemiology, 2016
Tamoxifen therapy for estrogen receptor-positive breast cancer reduces the risk of recurrence by approximately one-half. Cytochrome P-450 2D6, encoded by the polymorphic cytochrome P-450 2D6 gene (CYP2D6), oxidizes tamoxifen to its most active metabolites.
Ahern, Thomas P, Hertz, Daniel L, Damkier, Per, Ejlertsen, Bent, Hamilton-Dutoit, Stephen J; id_orcid 0000-0003-2158-3885, Rae, James M, Regan, Meredith M, Thompson, Alastair M, Lash, Timothy, Cronin-Fenton, Deirdre P   +9 more
openaire   +2 more sources

The Effect of Polymorphisms in the CYP2D6 and CYP2C9 Genes on the Clinical Efficacy of Tramadol and Ketorolac When Using the Accelerated Recovery Protocol in Patients With Uncomplicated Acute Calculous Cholecystitis Who Underwent Cholecystectomy

Неотложная медицинская помощь, 2020
Relevance. One of the key components of the accelerated recovery protocols (ARP), in addition to minimizing the surgical approach, is an adequate postoperative analgesia.
A. A. Muradyan, D. A. Blagovestnov, D. A. Sychev, P. A. Yartsev, M. L. Rogal, L. N. Kerimova, V. T. Koroshvili, I. A. Yepifanova   +7 more
doaj   +1 more source

Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol [PDF]

Biochemical Journal, 1996
Cytochrome P-450 2D6 (CYP2D6) is an important human drug-metabolizing enzyme responsible for the oxidation of more than 30 widely used therapeutic agents. The enzymes encoded by the published genomic [Kimura, Umeno, Skoda, Meyer and Gonzalez (1989) Am. J. Hum. Genet.
S W, Ellis, K, Rowland, M J, Ackland, E, Rekka, A P, Simula, M S, Lennard, C R, Wolf, G T, Tucker   +7 more
openaire   +2 more sources

Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): the influence of gender and genetics (CYP2D6, COMT, 5-HTT). [PDF]

PLoS ONE, 2012
The synthetic psychostimulant MDMA (± 3,4-methylenedioxymethamphetamine, ecstasy) acts as an indirect serotonin, dopamine, and norepinephrine agonist and as a mechanism-based inhibitor of the cytochrome P-450 2D6 (CYP2D6).
Ricardo Pardo-Lozano, Magí Farré, Samanta Yubero-Lahoz, Brian O'Mathúna, Marta Torrens, Cristina Mustata, Clara Pérez-Mañá, Klaus Langohr, Elisabet Cuyàs, Marcel lí Carbó, Rafael de la Torre   +10 more
doaj   +1 more source

Citalopram in vitro metabolism in a beagle dog: A role for CYP2D15 in the production of toxic didesmethylcitalopram?

Veterinární Medicína, 2023
After administration of the serotonergic antidepressant citalopram (CIT) to beagle dogs, they may experience severe convulsive attacks in relation with considerably higher plasma concentrations of the metabolite didesmethyl-CIT (DDCIT), when compared to ...
B Rochat, E Paus, C Maitre, P Baumann
doaj   +1 more source

Network Pharmacology and Molecular Docking Analysis on Targets and Mechanisms of Berberine in Atypical Antipsychotic-Induced Metabolic Syndrome

Natural Product Communications, 2022
Berberine (BBR), an isoquinoline alkaloid, possesses multiply pharmacological effects as a potential therapeutic drug for antipsychotic-induced metabolic syndrome (MetS). However, the underlying therapeutic mechanisms have not been fully elucidated.
Zhuowei Huang, Xiaolan Liu
doaj   +1 more source

Genetic risk factors of cytolysis syndrome in the treatment of recrudescence of chronic cardiovascular diseases

Российский кардиологический журнал, 2018
Aim. To assess the clinical, biochemical, and genetic risk factors for the development of hepatocyte cytolysis syndrome in patients with a combination of fatty liver disease and recrudescence of chronic cardiovascular pathology.Material and methods.
N. V. Kokh, E. N. Voronina, T. V. Efremova, G. S. Soldatova, G. I. Lifshits   +4 more
doaj   +1 more source

Effect of hesperetin on the pharmacokinetics of metoprolol succinate in rats

Future Journal of Pharmaceutical Sciences, 2023
Background Metoprolol is a substrate of CYP3A4, 2B6, CYP2D6, CYP2C9, and p-glycoprotein (p-gp). Hesperetin was reported as an inhibitor of cytochrome P-450 (CYP) enzymes and p-gp. The objective of this study was to investigate the effect of hesperetin on
Ravindra Babu Pingili, Sridhar Vemulapalli, Surya Sandeep Mullapudi, Vijaya R. Dirisala, Harsha Sai Chanumolu, Naveen Babu Kilaru   +5 more
doaj   +1 more source

Association between low body weight and cytochrome P‐450 enzyme activity in patients with anorexia nervosa

Pharmacology Research & Perspectives, 2020
Very little is known to which extent severe underweight could affect cytochrome P‐450 (CYP) enzyme activity. In this study, 24 patients with anorexia nervosa at two occasions ingested single oral doses of five test drugs known to be metabolized by CYP1A2,
Pål Sandvik, Stian Lydersen, Solfrid Hegstad, Olav Spigset   +3 more
doaj   +1 more source